Program
uliledlimab
Also written as “TJ004309” and “Uliledlimab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Neoplasm Metastasis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TJ Biopharma | 21 open or running | phase 3since Apr 22, 2025 | Mar 17, 2020 | Aug 5, 2028phase 3 · NCT06984588 |
| I-Mab Biopharma US | 10 open or running | phase 2since Jul 12, 2021 | Jul 12, 2021 | none ahead |
| Tracon Pharmaceuticals | 10 open or running | phase 1since Feb 5, 2019 | Feb 5, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 5, 2019First study: phase 1 study in Neoplasm MetastasisNew to Tracon PharmaceuticalsTracon Pharmaceuticals · NCT03835949 · 36 enrolled · United States
- Mar 17, 2020TJ Biopharma's first study: phase 2 study in Advanced Solid TumorNew to TJ BiopharmaTJ Biopharma · NCT04322006 · 225 enrolled · China
- Jul 12, 2021I-Mab Biopharma US's first study: phase 2 study in Ovarian NeoplasmsNew to I-Mab Biopharma USI-Mab Biopharma US · NCT05001347 · 25 enrolled · United States
- Apr 22, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungTJ Biopharma · NCT06984588 · 450 enrolled · China
Ahead
- Aug 5, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungTJ Biopharma · NCT06984588
TargetBeta
“A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), ”NCIt, by rule
Other programs on NT5E
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| oleclumab | AstraZeneca | phase 3 | 8 |
| quemliclustatrule | Arcus Biosciences | phase 3 | 7 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06984588Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | TJ Biopharma | Aug 5, 2028 | 450 |
| NCT05001347Ovarian Neoplasms · United States | 2 | Completed | I-Mab Biopharma US | Feb 8, 2023 | 25 |
| NCT04322006Advanced Solid Tumor · China | 2 | Completed | TJ Biopharma | Apr 30, 2025 | 225 |
| NCT03835949Neoplasm Metastasis · United States | 1 | UNKNOWN | Tracon Pharmaceuticals | Jun 2022 | 36 |
How it is read
Names in the registry
- “TJ004309”, 3 entries
- “Uliledlimab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
- Ovarian Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.